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1. Introduction  
Despite the recent advances in managing angina pectoris, many patients with coronary 
artery disease suffer from intractable pain. For those patients who have already failed 
optimal medical and surgical therapy, very few, if any, therapeutic options are available. 
However, spinal cord stimulation (SCS) may play a unique role in managing such refractory 
anginal pain.  
The analgesic effect of SCS has been known since 1967 when Norman Shealy was able to 
show electrical stimulation of the dorsal column of spinal cord suppressed the response to 
noxious stimulation in animal study and abolished pain in a patient with terminal cancer 
(Shealy et.al. 1967). The rationale for this technique was based on the "gate theory" of pain 
proposed by Melzack and Wall (Melzack &Wall 1965). The SCS has been used mostly in 
patients suffering chronic low back pain but has also been used successfully in a variety of 
other conditions including radiculopathy, complex regional pain syndrome, post-herpetic 
neuralgia, multiple sclerosis, and other types of neuropathic pain. Moreover, several studies 
were able to demonstrate the pain relieving effect of SCS in peripheral vascular disease, 
associated with an increase in local blood flow as well as angina pectoris (Augustinsson 
et.al., 1985; Cook et.al., 1976; Jacobs et.al., 1990; Murphy et.al., 1987).  
The use of electrical stimulation to manage angina was initially reported by Mannheimer 
et.al. (1982). The study showed that patients with severe angina pectoris treated with 
transcutaneous electrical nerve stimulation (TENS) reported decreased frequency and 
severity of anginal attacks, improved exercise tolerance, and a reduction in ST segment 
depression in electrocardiogram. But TENS unit is not suitable for long term therapy due to 
skin irritation and the stimulation equipment often restricted physical activity.  
Murphy et.al. (1987) placed SCS in the dorsal column in 10 patients with intractable angina 
pectoris. All patients were suffering with severe intractable angina pectoris, unresponsive to 
maximal medical therapy and not suitable for coronary artery bypass surgery, and all had 
angina at rest or on minimal exertion. Three patients had suffered myocardial infarction 
previously, and five patients had previously undergone coronary artery bypass surgery. The 
patients were typically on ǃ-blocker, calcium channel blocker, diuretics, and topical or 
sublingual nitroglycerin as needed. 
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All patients reported excellent results following the implantation with a significant decrease 
in both severity and frequency of angina attacks. All patients were able to reduce sublingual 
nitroglycerin requirement. One patient has returned to work. Three patients who 
experienced recurrence of angina, one had previously documented myocardial infarction 
(MI) and coronary artery bypass graft (CABG). He had two episodes of angina pectoris after 
almost 3 years after the implant.  
In another patient angina recurred for the first time 2 years after SCS. A third patient 
complained of a return of angina in a new location, not covered by the area of dorsal column 
stimulation. Insertion of an additional electrode succeeded in relieving the new angina. 
Three patients have died of complications related to their ischemic heart disease, 5 to 32 
months after the SCS implant. Another patient died of cardiogenic shock from MI nearly 7 
months after the implantation.  
Mannheimer et.al. (1988 & 1998) showed that SCS increased patients' tolerance to elevated 
heart rate under the controlled pacing. At the heart rate comparable to that producing 
angina, myocardial lactate production diminished, ST segment depression decreased, time 
to ST depression increased, and time to recovery from ST depression decreased respectively. 
SCS also reduced coronary sinus blood flow and myocardial oxygen consumption. 
Myocardial lactate level increased and the magnitude and duration of ST segment 
depression increased to the same values as during control pacing, indicating that 
myocardial ischemia during treatment with SCS can give rise to anginal pain. Thus spinal 
cord stimulation has an anti-anginal and anti-ischemic effect in severe coronary artery 
disease. These effects seem to be secondary to a decrease in myocardial oxygen 
consumption, and SCS does not mask the patient of a warning signal. 
Similarly, Sanderson et. al. (1992) studied effectiveness of SCS in 14 patients with severe 
intractable angina unresponsive to standard therapies including bypass grafting. After 
implantation of SCS units, the patients were assessed by a symptom questionnaire, treadmill 
exercise, and atrial pacing. There was a significant improvement of angina, and 
nitroglycerine usage decreased markedly. SCS increased exercise duration from a mean of 
414 to 478 seconds, and total ST segment depression was decreased both at maximum 
exercise (7.1 vs. 5.6 mm) and at 90% of the maximum control heart rate (3.5 vs. 2.6 mm). 
During the right atrial pacing, the maximum heart rate was reached before onset of angina 
(143 vs. 150 per min), and total ST segment depression was less at all heart rates. Benefit has 
persisted in some patients for over 2 years 
A retrospective analysis of patients from the Italian Multicenter Registry (Romano et.al. 
2000) showed that SCS is an effective therapy in patients with refractory angina pectoris, 
especially for those who cannot undergo revascularization procedure. One hundred and 
thirty patients (83 males, 47 females, mean age 74.8) were given SCS implantation for 
refractory angina and followed for 31.4 +/- 25.9 months. The follow-up data of 116 patients 
(89.2%) showed that SCS resulted in significant decrease in New York Heart Association 
(NYHA) functional class from 2.5 to 1.5 (p < 0.01). During the follow-up 41 patients (35.3%) 
died, and 14.2% developed a new acute MI. The annual total mortality rate was 6.5%, 
whereas the cardiac mortality rate was 5%. Compared to the survivors, patients who died 
showed a higher incidence of left ventricular dysfunction, previous MI and bypass surgery 
at implantation. 
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2. Outcome studies 
A first long term outcome study performed by Sanderson et.al. (1994) confirmed that SCS is 
an effective and safe form of alternative therapy for the patient whose angina is 
unresponsive to conventional therapies. The results were from follow-up study over a 
period of 62 months on 23 patients who had SCS implanted for intractable angina 
unresponsive to standard therapy. Symptomatic improvement was good and persisted with 
a mean change of NYHA grade from 3.1 pre-operatively to 2.0 (P < 0.01) immediately after 
operations. Nitrite consumption fell markedly. Mean treadmill exercise time increased from 
407 to 499 sec (P < 0.01). Forty-eight hour ST segment monitoring in those with SCS showed 
a reduction of frequency and duration of ischemic events. There were three deaths, none of 
which were sudden or unexplained. Two patients had a myocardial infarction, which was 
associated with typical pain and not masked by the treatment.  
In a prospective, controlled study, Hautvast et.al. (1998) randomized patients with chronic 
intractable angina pectoris to 13 treatment and 12 control groups. Inclusion criteria included 
chronic intractable angina pectoris class III or IV based on the NYHA criteria, unresponsive 
to beta-blocking agents, calcium antagonists, and nitrates. Myocardial ischemia was 
documented by ≥0.1 mV ST depression during a treadmill exercise test, and coronary artery 
disease was documented by angiogram. Moreover, patients were not suitable for 
percutaneous coronary angioplasty or coronary artery bypass grafting. Exclusion criteria 
were the inability to perform an exercise test, cardiac stress test, and the anatomically 
unsuitable for stimulator implantation. The efficacy of SCS was evaluated for 6-week follow-
up of daily intermittent stimulation compared with baseline and with a control group. 
Compared with control, SCS group exercise duration and time to angina increased; anginal 
attacks and sublingual nitrate consumption and ischemic episodes on 48-hour 
electrocardiogram (ECG) decreased. ST-segment depression on the exercise ECG decreased 
at comparable workload. Anginal attacks and consumption of sublingual nitrates decreased, 
perceived quality of life increased, and pain decreased.  
In a larger prospective study, Mannheimer et.al. (1998) randomized 104 patients into SCS 
and CABG groups (SCS, 53; CABG, 51). The patients were assessed with respect to 
symptoms, exercise capacity, ECG changes during exercise, heart rate-blood pressure 
product, mortality, and cardiovascular morbidity before and 6 months after the operation. 
Both groups had satisfactory symptom relief (P<.0001), and there was no difference between 
SCS and CABG group. The CABG group had an increase in exercise capacity (P=.02), less 
ST-segment depression on maximum (P=.005) and comparable (P=.0009) workloads, and an 
increase in the heart rate-blood pressure product both at maximum (P=.0003) and similar 
(P=.03) workloads compared with the SCS group. Eight deaths occurred during the follow-
up period, 7 in the CABG group and 1 in the SCS group. On an intention-to-treat basis, the 
mortality rate was lower in the SCS group (P=.02). Cerebrovascular morbidity was also 
lower in the SCS group (P=.03). They concluded that efficacy of CABG and SCS to be 
equivalent in terms of symptom relief in this group of patients and concluded that SCS may 
be a good alternative for patients with an increased risk of surgical complications.  
3. Mechanism 
The mechanism of SCS induced anti-nociceptive response is not well understood. Several 
theories have been proposed and elucidated based on the previous investigations on both 
animal model and patients treated with SCS.  
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3.1 Sympathetic blockade 
The perception of pain during myocardial infarction is thought to be mediated by 
sympathetic afferent nerve fibers (Bonica et.al., 1990). Therefore, high thoracic epidural 
analgesia with local anesthetic can block cardiac afferent sympathetic fibers resulting in 
improved analgesia during myocardial infarction (Blomberg et. al., 1989). Mannheimer et. 
al. (1982; 1985) suggested that improved pain relief results in decreased sympathetic activity 
leading to improved blood flow.  
In animal study, stimulation of spinal cord at weak to moderate intensity (50 Hz; 0.2 msec; 
amplitude 2/3 of evoking muscle contraction) improved ischemic conditions by suppressing 
sympathetic activity to the effector organ (Linderoth et.al., 1991a). In peripheral ischemic 
model, sympathectomy prior to SCS implant abolished benefits (Linderoth et.al. 1991b), and 
blockade of sympathetic preganglionic with hexamethnium or guanethidine totally 
abolished vasodilator effects of SCS (Linderoth et.al. 1991b, 1994a). Moreover, selective 
pharmacological blockade of autonomic transmission with an ǂ-1 antagonist prazosine also 
prevented increase in blood flow with SCS.  
However at higher intensity stimulation (90% of motor threshold) Croom (1996a, 1996b) 
showed that SCS produced increased microvascular flow independent of hexamethomium 
or phentolamine, a ǂ-1 adrenergic receptor antagonist (Croom et.al., 1997). Under the 
similar stimulation intensity, Foreman et.al. (1998) showed that SCS attenuated intrinsic 
cardiac neuronal activity, and the markedly decreased activity of neurons during local 
occlusion of coronary blood flow to the left ventricle. In another animal study, Olgin et.al. 
(2002) demonstrated that thoracic SCS slowed the sinus rate and prolonged atrioventricular 
(AV) nodal conduction time. This effect was not eliminated by bilateral sympathectomy, 
while bilateral vagal transection completely eliminated effect. In addition, thoracic SCS did 
not change nitric oxide (NO) level at the coronary sinus. Hence, they attributed decreased 
sinus rate and prolonged AV conduction to activation of parasympathetic system by SCS 
mediated via the vagus nerve. 
Similarly, anti-anginal effect can be also achieved by SCS at higher intensity in human. 
Murphy et.al. (1987) first demonstrated a successful treatment of otherwise intractable 
angina pectoris at the range of amplitude: 3-7 volts, frequency: 80-100 Hz, and pulse width: 
250-500/sec. However, Sanderson et.al. (1995) used TENS in healthy volunteers and found 
weak association between TENS and an anti-sympathetic effect. Norsell et.al. (1997) have 
evaluated effect of SCS on myocardial and sympathetic tone in angina patients with SCS 
using norepinephrine (noradrenaline) spillover techniques. Their result showed very little 
effect of SCS in reducing cardiac sympathetic activity. Although overall sympathetic activity 
was decreased, they postulated this to reduced oxygen demand. In addition, Robertson et.al. 
(1983) studied plasma catecholamine levels in 10 patients with frequent spontaneous 
episodes of coronary artery spasm to evaluate the role of the sympathetic nervous system. 
Patients were evaluated for peripheral venous norepinephrine in supine and upright 
postures, urinary excretion of catecholamines, and functional testing of the sympathetic 
nervous system. Results showed that there were no changes in arterial and coronary sinus 
levels of norepinephrine and epinephrine drawn early in ischemia compared to the control. 
Plasma epinephrine levels, higher in arterial than coronary sinus samples, rose significantly 
only late in ischemia, hence generalized sympathetic nervous system activation is unlikely 
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to be the sole cause of angina. Hence association between SCS induced relief of angina and 
anti-sympathetic effect is not robust.  
3.2 Blood flow 
Although SCS proved to have beneficial effects such as decreased anginal time, decreased 
duration and magnitude of ST segment depression during exercise compared with control 
values, but there were no significant changes in regional myocardial perfusion, as measured 
by positron emission tomography (PET) during exercise (De Landsherre, 1992). The 
previous studies have shown that TENS treatment failed to increase coronary sinus blood 
flow for patients with angina pectoris although anti-ischemic effect has been shown with 
improved myocardial lactate metabolism.(Cohen et.al., 1966; Emanuelssonm 1987; 
Mannheimer, 1989). Thus, literature studies do not support the hypothesis that the anti-
ischemic effect of SCS is due to increase in coronary artery blood flow.  
3.3 Oxygen demand and supply balance 
The coronary venous oxygen tension is relatively constant during changes in myocardial 
oxygen consumption, and number of literature studies hinted that the coronary blood flow 
depends largely on autoregulatory mechanisms (Mosher, 1964; Miller, 1979). The animal 
study by Knabb (1983) showed a linear correlation between myocardial oxygen 
consumption and coronary blood flow. Coronary physiology study by Feigl (1983) showed 
that ǃ-blockade gives rise to a reduction in both oxygen consumption and blood flow but 
did not affect the relation between these variables. It is possible that myocardial hypoxia 
leads to an increased concentration of adenosine, which produces arteriolar vasodilatation 
and an increase in blood flow, thus compensating for the decrease in myocardial oxygen 
tension. If SCS results in decrease in myocardial oxygen consumption, there will also be 
reduction in coronary blood flow.  
3.4 Direct pain inhibition 
Based on the original “gate theory” proposed by Melzack &Wall (1965), there is also reason 
to believe that spinal cord stimulation has a direct pain inhibiting effect on angina. The 
animal study by Chandler et. al. (1993) found that spinal cord stimulation attenuated 
anginal pain by reducing the activity of the spinal thalamic tract neurons which transmit 
nociceptive somatic and cardiac impulses. Two other studies (Kroger, 1989; Blomberg, 1989) 
suggested that treatment which has a direct pain inhibiting effect also decreases the activity 
in the cardiac sympathetic nerves, hence decreases the myocardial oxygen requirement. 
Nevertheless, direct pain inhibiting effect theory seems valid but not the singular 
interpretation of the analgesic effect of SCS. 
3.5 Endogenous opioids  
In animal study, Oliveras et.al (1977) showed that the analgesic effects obtained in the cat by 
central inferior raphe nucleus stimulation are greatly reduced by the administration of a 
specific opiate antagonist, naloxone. Moreover, Tonelli et.al. (1988) showed 50% increase in 
cerebrospinal ǃ-endorphin and ǃ-lipotropin levels for patients receiving good pain relief 
from SCS. These studies suggested link between SCS and endogenous opioid release, and 
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implicated the ǃ-endorphin response to SCS could have clinical value in predicting the 
success of treatment. On the contrary, Myerson et.al. (1977) showed that the pain relief 
produced by SCS is not reversed by naloxone. 
The release of endogenous opioid via SCS may depend on stimulation frequency. Han et.al, 
(1991) studied two groups of patients receiving low-frequency (2 Hz) and high-frequency 
(100 Hz) transcutaneous nerve stimulation (TENS). The cerebrospinal fluid (CSF) sample 
obtained before and after stimulation showed that low frequency stimulation resulted in a 
significant increase (367%, P < 0.05) of met-enkephalin but not dynorphin A, whereas high-
frequency (100 Hz) produced a 49% increase in dynorphin A (P < 0.01) but not met-
enkephalin. This is consistent with findings observed by Fei et.al. (1987) in animal 
experiments where low-frequency stimulation releases Met-enkephalin and high-frequency 
stimulation dynorphin A. The analgesia induced by low-frequency stimulation was readily 
reversed by naloxone and, therefore, probably mediated via mu-receptors; whereas 
analgesia induced by high-frequency stimulation required much higher doses of naloxone 
for reversal but was easily reversed by a kappa-receptor antagonist, indicating that the 
effects were mediated via kappa-receptors (Han et.al., 1986). Since dynorphins are preferred 
ligands for kappa-receptors, these studies strongly suggested that the opioid mechanism 
stimulated by high-frequency stimulation may be dynorphinergic. 
3.6 Amino acids and peptides 
The previous studies have shown that SCS can induce release of inhibitory amino acids such 
as substance P (SP), serotonin (5HT), Ǆ-amino butyric acid (GABA), and glycine in the 
cerebral spinal fluid (CSF) (Linderoth et.al.1992, 1994b; Myerson et.al., 1985; Duggan & 
Foong 1985; Simpson et.al., 1993). The antinociceptive properties of these substances are 
well documented depending on the location of administration in the central nerve system 
(CNS). Stiller et.al.(1996) showed that dysfunction of the spinal GABA system caused by the 
nerve damage in rats displayed tactile allodynia with significantly lower GABA in the 
dorsal horn compared to the control; while those responded to SCS showed dramatic 
increase in GABA and normalized withdrawal threshold. Moreover, the beneficial effect of 
SCS on allodynia could be reversed by the intrathecal injection of GABA-B antagonist; while 
the animals which failed to normalize tactile threshold due to the nerve lesion, intrathecal 
injection of GABA agonist (e.g., baclofen) increased threshold (Cui et.al., 1996). 
The benefit of SCS may not be limited to the increased release of inhibitory 
neurotransmitters. Kangra et.al. (1991) and Hao (1993) showed that SCS can also decrease 
release of excitatory amino acids such as glutamate and aspartate in the dorsal horn; hence 
further modulating pain transmission. Cui et.al. (1997 & 1998) showed that SCS can also 
activate release of adenosine, and simultaneous activation of GABA-B and adenosine A-1 
receptors may exert synergistic action. The beneficial effect of SCS is completely abolished 
when both of these receptors are blocked at the same time. They have also observed that 
injection of GABA-B and adenosine simultaneously can potentiate the effect of SCS on 
animals, however human trial data is equivocal. 
3.7 Redistribution of blood flow 
Hautvast et. al. (1996) has shown that spinal cord stimulation at T1 induces the 
redistribution of myocardial blood flow, resulting in a decrease in angina pectoris attacks. 
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The study demonstrated that spinal cord stimulation modulates regional cerebral blood 
flow (rCBF) in brain areas known to be involved in cardiovascular control and in areas 
associated with nociception. They postulated that the anti-anginal effect of SCS may 
therefore be the result of centrally mediated analgesic effects.  
Mobilia et.al. (1998) studied 15 patients who already had SCS implanted for refractory angina 
pectoris. Eight patients had a previous MI and four patients had undergone a 
revascularization procedure. All patient underwent two positron emission tomographies 
(PET) with nitrogen-13-ammonia as the perfusion tracer. The first one was performed with the 
stimulator switched off for at least 20 hours, and the second one with the stimulator switched 
on for at least 4 hours. The quantitative evaluation of regional mean blood flow (MBF) showed 
an increase in regional myocardial perfusion with the stimulator was observed in 47 (62%) out 
of 75 regions studied. Hence they concluded that the beneficial effects of SCS in refractory 
angina may be associated with an increase in mean MBF and to a redistribution of MBF 
between the regions with low or normal basal flow and the regions with high basal flow. 
Murray et.al, (2000) has elegantly explained redistribution model of SCS on myocardial 
blood flow citing findings by Crea et.al. (1989) and Gaspardone et.al. (1993). The similarities 
between SCS and theophylline in angina treatment are such that both seem to improve 
exercise capacity, and anti-ischemic action does not appear to be mediated by systemic 
hemodynamic effects or by stenosis dilation. Therefore, the improvement of myocardial 
ischemia from SCS is probably due to redistribution of coronary blood flow toward the 
underperfused areas of myocardium.  
At present the exact mechanism of action of neurostimulation is not known. All of the above 
mechanisms have been sought, and it is possible that more than one of them is responsible 
for the results of neurostimulation. 
4. Surgical technique and stimulation equipment 
The SCS lead is typically implanted in the operating room using sterile technique. Under the 
fluoroscopy guided technique, upper thoracic (T4 toT6 interspace) interspace is entered 
using Touhy needle to access epidural space. Usually single SCS lead is advanced up to C7 
to T2 level. The procedure is performed under local anesthesia to allow the patient to 
communicate with the physician during the intraoperative testing. The electrode position is 
adjusted during the intraoperative testing such that the patient feels a paresthesia in the 
region of anginal pain. The ideal position is when the stimulation produces a paresthesia in 
the precordial area and spreading into the left arms as the current intensity is increased. 
In order to enter epidural space at T4 to T5 interspace, skin entry point of Touhy needles is 
marked approximately 1 to 2 vertebral levels inferiorly. A 5 to 7 cm vertical skin incision is 
made from the needle entry point approximately one finger breadth lateral to the midline. The 
subcutaneous tissues are then cut down deep using bovie until dorsal column fascia is 
visualized. Then at the top of the incision, a Touhy needle is advanced toward epidural space 1 
to 1 ½ levels above the entry site using paramedian approach at no greater than 45 degree 
approach using loss of resistance technique. The electrode tip is typically placed a few 
millimeters to the left of midline at the level of C7 to T2 (Figure 1) under the fluoroscopy 
guidance. Following the successful intraoperative testing, the electrode is sutured to the fascia 
using anchoring device. The pulse generator is typically placed in a subcutaneous pocket 
below the left costal arch or gluteal region. The lead is then tunnelled subcutaneously from the 
www.intechopen.com
Coronary Artery Disease 
 – Current Concepts in Epidemiology, Pathophysiology, Diagnostics and Treatment 264 
anchor site to the generator site. The pulse generator is then interrogated to ensure good lead 
connection. Antibiotic prophylaxis is required for implantable devices. Prophylactic antibiotics 
must be administered to the patient within 1 hour prior to surgical incision. Studies show that 
a single preoperative dose of antibiotic is as effective as a 5-day course of postoperative 
therapy assuming an uncomplicated procedure. Duration of prophylaxis beyond 24 hours or 
use of  post operative antibiotics are generally not recommended (The Medical Letter 2004; 
Fabian et.al., 1992; Bozorgzadeh et.al., 1999; Luchette et.al., 2006).  
 
Fig. 1. SCS lead placement at upper thoracic spine. 
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5. Indications and patient selection 
The patients with refractory angina pectoris referred to our pain clinic by cardiologist 
usually has exhausted optimal therapeutic modalities including pharmacotherapy (ǃ-
blocker, calcium channel antagonist, vasodilator), surgical (e.g., coronary artery bypass graft 
(CABG), percutaneous transluminal coronary angioplasty (PTCA), stent placement, etc), and 
often maintained on anticoagulant and potent opioid analgesics which referring physicians 
are uncomfortable sustaining. Therefore, these patients are considered inoperable and 
untreatable. The inclusion and exclusion criteria are well described in Table 1 (De Vries et.al. 
2007). The algorithmic approach to angina pectoris depicted in Figure 2 (Kleef et.al. 2011) 
shows that SCS has its niche as the last resort treatment for managing refractory angina. 
In the United States, use of SCS for angina is still considered “off label.” Hence there are 
considerable obstacles to obtaining health insurance preauthorization. The prior treatment 
history is rigorously scrutinized, and often requires peer to peer review between the treating 
physician and physicians representing insurance company. Such process leads to further 
delay in providing treatment in a timely manner, and patients tend to become sub-optimal 
for the procedure. Therefore, the use of SCS for angina is not as common in the United 
States compared to Europe. 
 
Inclusion criteria 
1. Severe chest pain (NYHA classes III–IV or VAS score >7) 
2. Optimal tolerated pharmacological therapy 
3. Significant coronary artery disease (i.e. >1 stenosis of 75%) 
4. Not eligible for Percutaneous Transluminal Intervention or Coronary Artery Bypass Surgery 
5. No prognostic benefit from surgical revascularization (according to guidelines) 
6. Patient considered intellectually capable to manage the SCS device 
7. No acute coronary syndrome during last 3 months 
Exclusion criteria 
1. Myocardial infarction within the last 3 months 
2. Uncontrolled disease such as hypertension or diabetes mellitus 
3. Personality disorders or psychological instability 
4. Pregnancy 
5. Implantable cardioverter defibrillator (ICD) and pacemaker dependency 
6. (Local) infections 
7. Insurmountable spinal anatomy 
8. Contraindication to withheld anti-platelet agents or coumadins 
9. Addictive behavior 
*De Vries et.al. (2007). With permission 
Table 1. Inclusion and exclusion criteria SCS for ischemic heart disease (IHD)* 
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Fig. 2. Algorithm for the treatment of refractory angina pectoris (Kleef et.al. 2011). With 
permission. 
6. Cost effectiveness 
The cost-effectiveness of spinal cord stimulation in patients with intractable angina has been 
assessed by Merry et.al. (2001). The cost of healthcare utilization by patients suffering from 
intractable angina, unsuitable for coronary revascularization, before and after treatment 
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with spinal cord stimulation on eight patients. Information on consumption of specified 
medical resources for the twelve months preceding implantation, the implantation period, 
and the twelve months following implantation was collected. Where available, data were 
also collected for the eighteen months preceding and following treatment. 
The six patients with successful stimulation spent fewer days in hospital (p=0.028) and 
consumed fewer resources (p=0.046) following implantation than in the period before 
implantation. The two patients for whom spinal cord stimulation was unsuccessful spent 
more days in hospital and consumed more resources in the twelve months following, than 
in the twelve months preceding attempted implantation. Extrapolation of data for all eight 
patients suggests that, on average, the cost of implanting a spinal cord stimulator will be 
recovered in approximately fifteen months. 
The retrospective study by Rasmussen et.al. (2004) assessed economic significances of SCS 
treatment on 18 consecutive patients. Before implantation of the SCS system, the patients 
were in a TENS treatment for 2–11 months. At the time of implant all patients were in 
NYHA functional group III/IV. The study is based on cost data from the year prior to start 
of TENS treatment compared with the year after implantation of the SCS system. They 
found that SCS is effective in reducing hospital and non-hospital related expenses. 
Several additional studies have also showed cost effectiveness following the SCS implantation. 
The 2-year follow-up of the 104 patients participating in the Electrical Stimulation versus 
Coronary Artery Bypass Surgery in Severe Angina Pectoris (ESBY) study by Andréll et.al. 
(2003) found that SCS is less expensive than coronary artery bypass grafting in treating angina 
pectoris. The SCS group had fewer hospitalization days related to the primary procedure and 
to cardiac events. A systematic review by Taylor et. al. (2004) demonstrated that the initial 
costs of the SCS are offset by a reduction in post-implant healthcare demand and costs.  
Murray et al. (1999) showed that the average time the patients were in the hospital after 
revascularization was 8.3 days per year versus 2.5 days per year after SCS. The authors 
confirmed that SCS was effective in preventing hospital admissions in patients with 
refractory angina. 
7. Stimulation parameter 
Stimulation parameters are usually different for each patient as stimulation is 
individualized to produce optimal relief in each patient. Our own experience and published 
parameter range for angina vary widely. For the purpose of reference, the range of 
stimulation parameters published is: pulse amplitude 1-10 volt, frequency 80-100 Hz, pulse 
width 150 to 500 µsec (Murphy et.al. 1987; Hautvast et. al. 1997; Gersbach et.al. 2001). 
8. Complications 
The major complications of SCS implant are rare, and most complications are minor and 
limited to superficial infection, lead migrations, battery failure and electrode fractures (De 
jongste et.al. 1994 &2000). The overall complication rate in the literature is up to 12% (Borjesson 
et.al. 2008), but the complication rate is highly dependent on implanter’s experience, technique, 
and patient factor. It seems logical to expect higher complication rate from the inexperienced 
implanter. The earlier studies showed higher incidence of lead migration (De Jongste and 
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Staal, 1993; Jessurun et.al., 1997). But our own experience over last 10 years show dramatic 
decrease in lead migration in part attributed to improved lead anchor technologies.  
Discomfort at implantable electrical pulse generator (IPG) sites is not uncommon and often 
results in persistent pain in patients with spinal cord stimulator. The IPG is most frequently 
implanted in the gluteal region to take advantage of the natural cushion provided by the 
abundance of adipose tissue in the buttock area. However, IPG sites are subject to 
unrelenting pressure and trauma of daily activities such as sitting, lying down, and bending 
leading to cutaneous hyperalgesia. Often, patients require additional analgesics or revision 
of the IPG pocket to control pain. A retrospective review of 20 patients at our institution 
(Huh and Kuo, 2011) who underwent revision due to painful IPG site (9 relocation versus 11 
deep implantation at the same site) showed that decrease in pain score was significant 
within each group (p < 0.001), but no significant difference in pain was found between the 
two techniques (p = 0.5779). However, we recommend deep re-implantation of the IPG at 
the original site over the relocation due to the simplicity of the procedure. Re-implantation 
does not require creating a new pocket, and it is not limited by the length of the electrode. 
9. Conclusion 
Spinal cord stimulation (SCS) is an alternative therapy for patients with intractable angina 
who has not responded to standard therapies. Studies shows that SCS provide relief from 
the angina pain, decrease use of analgesia and nitrates, decrease incidence of ischemic 
attacks, improve heart function and quality of life 
Although there is abundant evidence from Europe to show the benefits of SCS for refractory 
angina pectoris, the use of SCS in the United States is still considered experimental. Hence at 
large academic institutions, CABG is still the most commonly performed procedure for severe 
CAD. Health insurance coverage for SCS is challenging for angina pectoris. The scope of the 
disease process is enormous, and future direction begs to invest in a large multicenter 
prospective study to obtain Food and Drug Administration approval to benefit patients 
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